Search results for "Trie"

showing 10 items of 4468 documents

The Applicability of a Checklist for the Diagnosis and Treatment of Exocrine Pancreatic Insufficiency: Results of the Italian Exocrine Pancreatic Ins…

2020

Objective To evaluate a rapid checklist capable of identifying exocrine pancreatic insufficiency in outpatients. Methods Prospective observational study of a multicenter cohort. Results One hundred and two patients were enrolled; 61.8% of the patients had medically-treated benign or malignant pancreatic disease, and 38.2% had a pancreatic resection. Visual examination of the feces was evaluated in 84 patients and it was related to steatorrhea in 51 patients (50.0%). Receiver operating characteristic curves were evaluated for each symptom or clinical sign and four of them (ie, increase in daily bowel movements, number of bowel movements, fatty stools, >10% weight loss) had a satisfactory …

AdultMalemedicine.medical_specialtyPancreatic diseaseSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismPancreatic Extractsmedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineEndocrinologyWeight lossInternal medicineOutpatientsInternal MedicinemedicineHumansEnzyme Replacement TherapyProspective StudiesRegistriesExocrine pancreatic insufficiencyPancreas enzymeAgedHepatologybusiness.industrydigestive oral and skin physiologyFeces analysisexocrine pancreatic insufficiency fecal elastase-1 maldigestion pancreatic diseases steatorrhea.Middle Agedmedicine.diseaseChecklistSteatorrheaPancreatic Function TestsItalyROC Curve030220 oncology & carcinogenesisPancreatectomyExocrine Pancreatic InsufficiencyFemale030211 gastroenterology & hepatologymedicine.symptombusiness
researchProduct

Recent Trends in Survival of Patients With Pancreatic Cancer in Germany and the United States

2016

Objectives Survival improvement for pancreatic cancer has not been observed in the last 4 decades. We report the most up-to-date population-based relative survival (RS) estimates and recent trends in Germany and the United States. Methods Data for patients diagnosed in 1997 to 2010 and followed up to 2010 were drawn from 12 population-based German cancer registries and the US SEER (Surveillance, Epidemiology and End Results) 13 registries database. Using period analysis, 5-year RS for 2007 to 2010 was derived. Model-based period analysis was used to assess 5-year RS time trends, 2002-2010. Results In total 28,977 (Germany) and 34,793 (United States) patients aged 15 to 74 years were analyze…

AdultMalemedicine.medical_specialtyPathologyAdolescentEndocrinology Diabetes and MetabolismPopulationYoung Adult03 medical and health sciencesAge DistributionSex Factors0302 clinical medicineEndocrinologyGermanyPancreatic cancerEpidemiologyInternal MedicineHumansMedicineRegistriesYoung adulteducationSurvival analysisAgedNeoplasm StagingAged 80 and overeducation.field_of_studyHepatologyRelative survivalbusiness.industryAge FactorsCancerMiddle AgedPrognosismedicine.diseaseSurvival AnalysisUnited StatesPancreatic NeoplasmsSurvival Rate030220 oncology & carcinogenesisPeriod AnalysisFemale030211 gastroenterology & hepatologybusinessSEER ProgramDemographyPancreas
researchProduct

How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy.

2005

Abstract The epidemiology of pertussis in Italy is described by using data from the statutory notification system and from seroepidemiology studies. Starting from the 1990s, the incidence of pertussis in Italy has shown a sharp decline and is now at the lowest level ever reached. During this time period vaccination coverage has increased from 88% in 1998 to 95% in 2003. In 1996–97, the prevalence of subjects with levels of IgG antibodies against PT greater than 2 EU/ml was 77.6%. The increase in vaccination coverage will probably change the pattern of disease transmission and increase the number of susceptible adults, unless administration of booster doses to adolescents and adults is consi…

AdultMalemedicine.medical_specialtyPediatricsAdolescentWhooping CoughImmunization SecondaryMandatory ProgramsMass VaccinationPertussiSeroepidemiologic StudiesEpidemiologyMedicineHumansPertussis vaccinationRegistriesChildWhooping coughSeroepidemiologyVaccination coveragePertussis VaccineBooster (rocketry)General VeterinaryGeneral Immunology and Microbiologybusiness.industryIncidence (epidemiology)Public Health Environmental and Occupational HealthAge FactorsInfantmedicine.diseaseAntibodies BacterialInfectious DiseasesItalyVaccination coverageChild PreschoolPopulation SurveillanceImmunologyMolecular MedicineFemalebusinessTos ferinaDisease transmissionVaccine
researchProduct

Three years of experience : the Italian registry and safety data update

2011

At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%. Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability…

AdultMalemedicine.medical_specialtyPediatricsMultiple SclerosisDermatologyDiseaseAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingmedicineHumansRegistriesAdverse effectbusiness.industryNatalizumabMultiple sclerosisGeneral Medicinemedicine.diseasePsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYsurveillance program; pharmacovigilance; multiple sclerosis; natalizumabPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurosurgerybusinessMultiple sclerosis NatalizumabSurveillance program Pharmacovigilancemedicine.drug
researchProduct

A Cohort Study of Childhood Cancer Incidence after Postnatal Diagnostic X-Ray Exposure

2009

Ionizing radiation is an established cause of cancer, yet little is known about the health effects of doses from diagnostic examinations in children. The risk of childhood cancer was studied in a cohort of 92.957 children who had been examined with diagnostic X rays in a large German hospital during 1976-2003. Radiation doses were reconstructed using the individual dose area product and other exposure parameters, together with conversion coefficients developed specifically for the medical devices and standards used at the radiology department. Newly diagnosed cancers occurring between 1980 and 2006 were determined through record linkage to the German Childhood Cancer Registry. The median ra…

AdultMalemedicine.medical_specialtyPediatricsNeoplasms Radiation-InducedAdolescentBiophysicsCohort StudiesGermanyNeoplasmsRadiation IonizingEpidemiologymedicineHumansRadiology Nuclear Medicine and imagingRegistriesChildChildhood Cancer RegistryRadiationbusiness.industryIncidenceX-RaysIncidence (epidemiology)InfantCancermedicine.diseaseLeukemia2nd malignant neoplasms; ionizing-radiation; computed-tomography; ultrasound exposure; young-children; risk-factors; in-utero; survivors; leukemia; irradiationChild PreschoolMultivariate AnalysisCohortFemalebusinessRecord linkageCohort studyRadiation Research
researchProduct

Immune tolerance induction with moroctocog-alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with high-titre inhibitors: D…

2019

Background: The appearance of inhibitors is the most serious complication in haemophilia A (HA) patients. The primary objective is their eradication. Up to date, immune tolerance induction (ITI) was the only therapeutic option to achieve this. Aim: To assess the efficacy of moroctocog-alpha as an ITI regimen in a population of HA patients with high-titre inhibitors. Methods: The REF.IT Registry is a retrospective-prospective study that collected data on all patients with HA and high-titre inhibitors treated with moroctocog-alpha as an ITI regimen at twelve Italian Haemophilia Centres. Results: We enrolled 27 patients, 85.2% were children. All patients were high responders, 88.9% had severe …

AdultMalemedicine.medical_specialtyPopulationHaemophilia AAlpha (ethology)030204 cardiovascular system & hematologyHaemophiliaHemophilia Ahaemophilia A with inhibitors; immune tolerance induction; moroctocog-alpha; poor-prognosis ITI patients; Adult; Child; Child Preschool; Factor VIII; Female; Hemophilia A; Humans; Immune Tolerance; Italy; Male; Prospective Studies; Retrospective Studies; Risk Factors; RegistriesImmune tolerance03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineImmune ToleranceMedicineHumansProspective StudiesRegistrieseducationHigh titrePreschoolChildGenetics (clinical)Retrospective Studiesimmune tolerance inductioneducation.field_of_studyFactor VIIIbusiness.industryHematologyGeneral Medicinehaemophilia A with inhibitormedicine.diseasepoor-prognosis ITI patientsRegimenItalymoroctocog-alphaChild PreschoolFemalebusinessComplicationhaemophilia A with inhibitors030215 immunologyHaemophilia : the official journal of the World Federation of HemophiliaREFERENCES
researchProduct

The INTERPHONE study: design, epidemiological methods, and description of the study population

2007

The very rapid worldwide increase in mobile phone use in the last decade has generated considerable interest in the possible health effects of exposure to radio frequency (RF) fields. A multinational case-control study, INTERPHONE, was set-up to investigate whether mobile phone use increases the risk of cancer and, more specifically, whether the RF fields emitted by mobile phones are carcinogenic. The study focused on tumours arising in the tissues most exposed to RF fields from mobile phones: glioma, meningioma, acoustic neurinoma and parotid gland tumours. In addition to a detailed history of mobile phone use, information was collected on a number of known and potential risk factors for t…

AdultMalemedicine.medical_specialtyRadio WavesEpidemiologyPopulationEpidemiological methodRisk AssessmentInterviews as Topic03 medical and health sciences0302 clinical medicineEnvironmental healthNeoplasmsEpidemiologymedicineHumans030212 general & internal medicineeducationeducation.field_of_studybusiness.industryDeveloped CountriesParotid gland tumourMiddle AgedSurgeryAcoustic neurinomaMobile phone030220 oncology & carcinogenesisEpidemiologic Research DesignCellular PhonePopulation studyFemaleRisk assessmentbusinessEpidemiologic MethodsCell PhoneEuropean Journal of Epidemiology
researchProduct

The Severe Asthma Network in Italy: Findings and Perspectives

2019

Background Severe Asthma Network in Italy (SANI) is a registry of patients recruited by accredited centers on severe asthma. Objective To analyze epidemiological, clinical, inflammatory, functional, and treatment characteristics of severe asthmatics from the SANI registry. Methods All consecutive patients with severe asthma were included into the registry, without exclusion criteria to have real-life data on demographics, asthma control, treatments (including biologics), inflammatory biomarkers, and comorbidities. Results A total of 437 patients (mean age: 54.1 years, 57.2% females, 70.7% atopics, 94.5% in Global Initiative for Asthma severity step V) were enrolled into the study. The mean …

AdultMalemedicine.medical_specialtyRegistrySevere asthmaExacerbationBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Immunology and AllergyOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioComorbiditiesAtopy03 medical and health sciencesBronchiectasi0302 clinical medicineFood allergyInternal medicineLate-onset asthmaNasal polypsBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Adult; Aged; Asthma; Bronchiectasis; Comorbidity; Eosinophils; Female; Humans; Immunoglobulin E; Italy; Male; Middle Aged; Nasal Polyps; Registries; RhinitisMedicineHumansBronchiectasis Comorbidities Late-onset asthma Nasal polyps Registry SANI Severe asthma Immunology and AllergyImmunology and Allergy030212 general & internal medicineRegistriesAsthmaAgedRhinitisBronchiectasisbusiness.industryNasal polypSANIImmunoglobulin EMiddle Agedmedicine.diseaseAsthmaBronchiectasisEosinophils030228 respiratory systemItalyAsthma Control QuestionnaireFemaleComorbiditiebusinessMepolizumabmedicine.drug
researchProduct

The epidemiology of mumps in Italy.

2008

In Italy, although vaccination has been recommended for a number of years, vaccination coverage for mumps is still sub-optimal. The objective of the present study was to evaluate the seroprevalence of mumps antibodies in the Italian population, stratified by age, gender and geographical area. The proportion of individuals positive for mumps antibodies remained stable in the age classes 0–11 months and 1 year (25.4% and 30.8%, respectively) and showed a continuous increase after the second year of life. The percentage of susceptible individuals was higher than 20% in persons 2–14 years of age and exceeded 10% in persons 15–39 years of age. No statistically significant differences were observ…

AdultMalemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicaAdolescentDatabases FactualMumps; Seroprevalence; Vaccination; Adolescent; Adult; Age Factors; Child; Child Preschool; Databases Factual; Disease Outbreaks; Female; Humans; Immunoglobulin G; Infant; Italy; Male; Middle Aged; Mumps; Registries; Seroepidemiologic Studiesmumps; seroprevalence; vaccinationSerologyDisease OutbreaksDatabasesSeroepidemiologic StudiesEpidemiologymedicineSeroprevalenceHumansRegistriesPreschoolChildMumpsFactualGeneral VeterinaryGeneral Immunology and Microbiologyseroprevalencebusiness.industryPublic Health Environmental and Occupational HealthAge FactorsInfantMiddle AgedvaccinationItalian populationVirologyVaccinationMumps Seroprevalence VaccinationInfectious DiseasesItalyVaccination coverageChild PreschoolImmunoglobulin GMolecular MedicineFemaleViral diseasebusinessDemographyVaccine
researchProduct

Variable association of 24-h peripheral and central hemodynamics and stiffness with hypertension-mediated organ damage: the VASOTENS Registry.

2020

Objective In this analysis of the telehealth-based Vascular health ASsessment Of The hypertENSive patients Registry, we checked how 24-h central and peripheral hemodynamics compare with hypertension-mediated organ damage (HMOD). Methods In 646 hypertensive patients (mean age 52 ± 16 years, 54% males, 65% treated) we obtained ambulatory brachial and central SBP and pulse pressure (PP), SBP, and PP variability, pulse wave velocity and augmentation index with a validated cuff-based technology. HMOD was defined by an increased left ventricular mass index (cardiac damage, evaluated in 482 patients), an increased intima-media thickness (vascular damage, n = 368), or a decreased estimated glomerul…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaPhysiologyarterial stiffness augmentation index blood pressure blood pressure telemonitoring central arterial pressure hypertension pulse wave velocity vascular biomarkersRenal functionHemodynamicsBlood Pressure030204 cardiovascular system & hematologyPulse Wave AnalysisKidneyCarotid Intima-Media Thickness03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineRegistriesPulse wave velocityAgedSettore MED/14 - Nefrologiabusiness.industryHemodynamicsBlood Pressure DeterminationOdds ratioBlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseasePulse pressureBlood pressureAmbulatoryHypertensionCardiologyArterial stiffnessFemaleCardiology and Cardiovascular MedicinebusinessGlomerular Filtration RateJournal of hypertension
researchProduct